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Introduction
The increasing prevalence of diabetes mellitus (DM) worldwide has led to a situation where approximately 360 million people had DM in 2011, of whom more than 95% were diagnosed with type 2 DM (T2DM). Over 60% of people with T2DM develop cardiovascular disease (CVD), a more severe and costly complication than retinopathy. Thus, CVD risk should be given a higher priority in T2DM population. The problem of CVD risk in diabetes is noticed as very important in Europe and that is why European Society of Cardiology (ESC) in collaboration with the European Association for the Study of Diabetes developed clinical practice guidelines on diabetes, pre-diabetes, and CVD (last update in 2013) [1] . The management of cardiovascular (CV) risk in diabetes is also discussed in other ESC documents [2, 3] .
In 2009, the ARETAEUS 1 study was conducted and it showed that a great majority of patients with T2DM of short duration did not meet all of the treatment goals as recommended in the current practice guidelines [4, 5] . In 2011, Diabetes Poland [6] updated its recommended goals in diabetes treatment, and in 2012, ESC [2] updated its guidelines on cardiovascular prevention. Adherence to the updated guidelines has not been systematically assessed.
The main study aims were: 1) to assess the pharmacotherapy of T2DM patients and 2) to assess the degree to which the diabetic control criteria recommended in the current clinical practice guidelines developed by the Diabetes Poland [6, 7] (and ESC [2] ) are met. This paper reports on CV risk factors prevalence and CV risk management in the population with T2DM lasting for more than 10 years).
Methods
Detailed description of the ARETAEUS2--Grupa study design, protocol, questionnaire, inclusion criteria for the study, recruitment procedures of physicians and their patients and sample size calculations was published previously [8] . Briefly, ARETAEUS2-Grupa was a cross-sectional questionnaire-based study conducted in Poland (April-June 2012). The study included two groups of patients with T2DM: 1) diagnosed within the last 2 years and 2) diagnosed more than 10 years before the study commencement.
Treatment goal definitions from both Diabetes Poland [6, 7, 9] and ESC [1] [2] [3] guidelines were used. Diabetes Poland guidelines define treatment goals in T2DM patients as: glycated hemoglobin A1c (HbA1c) ≤ 7%, blood pressure (BP) < 140/90 mm Hg (this threshold was changed from 130/80 mm Hg in 2011), total cholesterol < 4.5 ml/L, low density lipoprotein cholesterol (LDL-C) < 2.6 mmol/L (< 1.8 mmol/L if coronary artery disease [CAD] is present), high density lipoprotein cholesterol (HDL-C) > 1.0 mmol/L in men (and > 1.3 in women), triglycerides (TG) < 1.7 mmol/L. ESC treatment goals are different in the aspect of BP (<140/80 [2] or < 140/85 mm Hg [1, 3] ) and LDL-C level < 2.6 mmol/L (< 1.8 mmol/L in very high risk patients defined as CAD or DM with one or more CV risk factors and/or target organ damage).
This paper concerns only patients with T2DM lasting > 10 years, participating in ARATAEUS2--Grupa Study, while the data on CV risk management in patients with T2DM of short duration will be reported separately.
Statistical analysis
We compared proportions of patients achieving treatment goals in the subgroups with c 2 test or Fischer's exact test (when the expected values in any of the cells of a contingency table were below 5). For the comparison of the means the t-test was used (for normal distribution), and the Mann-Whitney U test and Kruskal-Wallis test (for non-normal distribution of the variable). The distribution was estimated on the basis of skewness coefficient and graphical picture. The t-test for equal or non-equal variances was used depending on the result of the Levene's test. All statistical analyses were conducted using SPSS v 18.0.
Results
The patient and physician characteristics and the results related to diabetes control was described elsewhere [10] . Sixty per cent of all patients had HbA1c level above 7.0%.
Mean age of patients was 68 ± 10 years, 54% were female, mean body mass index (BMI) was 30. attack, 53% were smokers and 31% ex-smokers. Mean systolic/diastolic arterial pressure in participants with diagnosed hypertension was 139 ± ± 15/81 ± 10 mm Hg and among those without such diagnosis 127 ± 11/76 ± 7 mm Hg. The coincidence of various risk factors was very frequent ( Table 1) .
The mean lipid levels are presented in Table 2 . Total cholesterol treatment goal (< 4.5 mmol/L) was met in 34.5% of all patients, TG treatment goal [1, 3] ) and HDL-C treatment goal (> 1.0 mmol/L in men and > 1.3 mmol/L in women) in 38.2%. There were significant differences in the numbers of patients achieving these targets between patients with the diagnosis of lipid disorders (or taking hypolipidemic drugs) and without such a diagnosis (or not taking drugs). There were no significant differences between the subgroups using and not using statins (LDL-C treatment goal defined in Diabetes Poland guidelines was reached in 24.1% vs. 34.7% patients, respectively). The use of acetylsalicylic acid (ASA), statins, fibrates, and beta-blockers in the studied patients is shown in Table 3 . Most of patients with and without CAD were receiving ASA (90.3% and 60%, respectively) and statins (84.4% and 67.7%, respectively). Ninety per cent of patients with a history of myocardial infarction received beta-blocker (Table 3) . The use of medications in different age subgroups is presented in Figure 1 .
Percentages of patients falling into different categories of BP levels are shown in Table 4 .
Regarding BP control, the treatment goal outlined in the last 3 editions of Diabetes Poland guidelines [6, 7, 9] (i.e. 140/90 mm Hg) was met in 43.5% of the overall population. The percentage was significantly higher in the subgroup of patients without the diagnosis of hypertension and not taking antihypertensive drugs as compared with patients with the diagnosis of hypertension or taking antihypertensive drugs (79.4% vs. 39.6%; Fig. 2A ). The more restricted goal of BP below 130/80 mm Hg (which was used by Diabetes Poland in the guidelines until 2010 [11] when all study participants have already had T2DM) was achieved in 12.4% of patients. The patients were mainly treated with ≥ 3 antihypertensive drugs (Fig. 2B) . The majority received angiotensin converting enzyme inhibitor, beta-blocker, diuretic and calcium channel blocker; other drugs were used less frequently (Table 5 ). Combination antihypertensive drugs were used in 14.9% of patients.
All treatment goals (HbA1c ≤ 7.0%, BP < 140/90 mm Hg and LDL-C < 2.6 mmol/L [< 1.8 mmol/L if CAD]) were reached only by 8.2% of patients, any two goals by 26.3% of patients (HbA1c and BP goals in 14.9%, HbA1c and LDL-C goals in 5.8%, BP and LDL-C goals in 5.6%), one goal by 39.8% of patients (HbA1c goal in 13.6%, BP goal in 18.2%, LDL-C goal in 8.0%), none by 25.6% of patients. The percentages of patients reaching three or two goals were smaller if LDL-C treatment goal was defined according to ESC guidelines (4.5% and 25.2%, respectively). Figure 3 represents the results of the analysis of the number (and type) of treatment goals met in the differently predefined subgroups of patients (with or without previous CV events; receiving different number of antihypertensive drugs, receiving and not receiving statins and fibrates).
Discussion
ARETAEUS2-Grupa Study is the first Polish study addressing specifically patients with T2DM of more than 10-year duration. In this paper, the data on CV risk factors profile and management are presented.
Other Polish studies, OPTIMO [12] and DYNAMIC-2 [13] , included respectively 24% and 16% of patients with T2DM of more than 10-year duration. In The Polish Diabetes Registry for adults [14] , mean diabetes duration was 9.7 years. Achieving all of the treatment goals (HbA1c, BP and lipid values) was very uncommon in those studies (regardless of the goal definitions), and the proportion of patients achieving one or two of these goals was also unsatisfactory.
We used goal definitions from both Diabetes Poland [6, 7, 9] and ESC [1] [2] [3] guidelines which differ in some aspects (see above). Since the time of diagnosis in all patients participating in ARETAEUS2-Grupa Study was described here, the thresholds of good CV risk control have been changed. Those changes in the treatment goals and the inconsistency between the guidelines of leading scientific societies make the implementation of these guidelines even more difficult, although this cannot be used as an excuse and the only explanation for poor diabetes control. Additionally, some goals are not clearly defined and need ordering special diagnostic tests, which are not so easily available in an outpatient clinic. An example could be the LDL-C level according to ESC guidelines [2] , which was less frequently reached (in comparison to more clear goal of LDL-C control according to Diabetes Poland and previous ESC [15] guidelines -15.2% vs. 26.5%).
The treatment goals are less restrictive now and this is the first survey in which rate of achieving these new goals was studied. Our study shows that they are reached in more patients but the level is still unsatisfactory. We cannot exclude the possibility that physicians do not pay enough attenwww.cardiologyjournal.org tion to prevention and do not find time to explain to patients its importance, and that patients with chronic disease are tired of all restrictions (life style modifications and multidrug regimens).
It is worth mentioning that 56% of all patients have BP > 140/90 mm Hg, although the frequency of using 3 or more antihypertensive agents was high (30.7 and 31.7%, respectively). A substantial change in the number of antihypertensives used in 1 patient is to be noticed during the last decade -in Dynamic II study [13] , only 18.4% of patients received more than 2 of those agents. Therefore, it is possible that the problem of poor BP control is not connected with the number of drugs used but with adjustment of the dose or with patients' compliance. However, the frequency of using combination drugs seems to be too low (14%); physicians should be encouraged to use them more often, because it may improve compliance [16] .
The lipid control in our study participants is similar to that observed in the Polish Diabetes Registry for adults [14] -total cholesterol < 4.5 mmol/L was present in 34.5% vs. 32.6%, and TG < 1.7 mmol/L in 53.8% vs. 53.2% of patients. These data show some improvement as compared to the DEPAC survey [17] performed in Central and Eastern Europe (including Poland) at the time of accession to EU (2004) in which total cholesterol < 4.5 mmol/L was present in 19.7% and TG < 1.7 mmol/L in 43.5% of participants. Although the difference could also be attributed to the fact that DEPAC included only secondary care patients, which focuses on patients with advanced diabetic complications and requiring treatment intensifica- Numbers in brackets -number of valid questionnaires; *significant difference between patients with and without coronary heart disease (CAD); ^significant difference between patients with and without lipid control; #significant difference between patients with and without a history of myocardial infarction (MI); ESC -European Society of Cardiology; LDL -low density lipoprotein tion, our study included both primary and secondary care settings. It is needed to mention that in the current ACC/AHA guidelines on the treatment of blood cholesterol to reduce atherosclerotic CV risk in adults, the LDL goals are not defined any more [18] . According to these guidelines, the patients at the age 40-75 with diabetes and LDL-C level > 70 mg/dL (1.8 mmol/L) moderate or high-intensity statin therapy is recommended (dependent on LDL-C level < or > 189 mg/dL). Moderate and high doses of statins are defined as in clinical trials. However, this new approach was not accepted by European societies which still recommend that the ESC guidelines are followed [1, 2] . There are concerns that without obvious treatment goals the patient compliance can be worse.
The adherence to clinical practice guidelines is better when the recommendations are clear, simple and easy to follow (e.g. using specific drugs in specific clinical situations -ASA in CAD [90.3% of study participants with CAD received it] or Table 4 . Categories of blood pressure levels in patients with type 2 diabetes mellitus lasting for more than 10 years. This inconsistency of guidelines may contribute to possible overuse of ASA for primary prevention in T2DM in our study. Finally, it is necessary to mention that management of CV risk factors in diabetic patients is challenging and is regarded as unsatisfactory not only in Poland but also in other countries from EU and outside Europe [19] [20] [21] [22] [23] [24] . Of note, it was observed by Polish researchers [25] that control of CV risk factors was better in CAD patients than in diabetic patients, although still unsatisfactory in most of them; it shows that DM is still not perceived as dangerous and life-threatening as CAD.
Limitation of the study
Obviously, we realize that our study is not free from limitations. The cross-sectional design of the study does not provide us with long-term data. As a result of the different T2DM durations in the participants, the median or mean values of the parameters may not be informative. To get the representative sample of the population with T2DM of more than 10-year duration we randomly selected physicians participating in our study separately from diabetologists and non-diabetologists (stratified by size of the place of residence) and we introduced patient selection on a pseudo-random basis.
However, the data collected from the physicians were not verified and this may be associated with bias toward better results.
Another limitation is the fact that hypertension and lipid disorders were recognized on the basis of physician's opinion as well as the use of antihypertensive or hypolipidemic agents, respectively. This fact and the long duration of diabetes may be the reasons why the hypertension was recognized more often in our population than in other studied groups with diabetes.
Conclusions
The results of the ARETAEUS2-Grupa Study provide valuable information about CV risk factors prevalence and CV risk management in T2DM of more than 10-year duration. This information is useful for all people engaged directly or indirectly in the care of T2DM patients: doctors, nurses, university tutors and experts developing and implementing practice guidelines in Poland and other countries. It is obvious that new less restrictive treatment goals would be reached more frequently but significant improvement may still be achieved in the field of clinical practice guidelines implementation and CV prevention in T2DM population. Another component of successful treatment in chronic diseases is patients' awareness of the treatment goals, and more effort should be put into increasing compliance of the patients. It is also essential to elaborate the www.cardiologyjournal.org strategies to improve medical care in T2DM and surveillance of preventive-care practices and treatment goals among affected individuals for planning further initiatives that would reduce the burden of CV complications in T2DM patients.
